These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Use of apomorphine in Parkinson's disease. Stocchi F Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769 [TBL] [Abstract][Full Text] [Related]
27. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy. Fischer PA J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073 [TBL] [Abstract][Full Text] [Related]
28. [Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review]. Bode M Ugeskr Laeger; 2009 Oct; 171(41):2996-9. PubMed ID: 19814927 [TBL] [Abstract][Full Text] [Related]
29. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629 [TBL] [Abstract][Full Text] [Related]
30. [Pergolide: a useful agonist for the treatment of Parkinson disease]. Bonnet AM; Houeto JL Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908 [TBL] [Abstract][Full Text] [Related]
31. Ropinirole in the symptomatic treatment of Parkinson's disease. Brooks DJ; Torjanski N; Burn DJ J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630 [TBL] [Abstract][Full Text] [Related]
32. Identifying poor symptom control in Parkinson's disease. Scott L Nurs Times; 2006 Mar 21-27; 102(12):30-2. PubMed ID: 16594560 [TBL] [Abstract][Full Text] [Related]
33. Medical hazards of the internet: gambling in Parkinson's disease. Larner AJ Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457 [No Abstract] [Full Text] [Related]
34. [Current pharmacotherapy of Parkinson's disease]. Takáts A Orv Hetil; 2000 Mar; 141(10):483-8. PubMed ID: 10750400 [TBL] [Abstract][Full Text] [Related]
35. [Therapeutic effect of budipin in treating Parkinson's disease]. Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):197-8. PubMed ID: 4075906 [No Abstract] [Full Text] [Related]
36. Parkinson's: integrating the primary and secondary care guidelines. Macmahon D; Brooks D; Smith R Practitioner; 2000 Apr; 244(1609):370-8. PubMed ID: 10892059 [No Abstract] [Full Text] [Related]
37. Novel pharmacological targets for the treatment of Parkinson's disease. Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425 [TBL] [Abstract][Full Text] [Related]
38. Dihydroergocryptine in the treatment of Parkinson's disease. Bonuccelli U; D'Antonio P; D'Avino C; Piccini P; Muratorio A J Neural Transm Suppl; 1995; 45():239-45. PubMed ID: 8748631 [TBL] [Abstract][Full Text] [Related]
39. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease. Ruggieri S; Fabbrini G; Bramante L; DePandis F; Stocchi F; Barbanti P; Vacca L; Manfredi M Adv Neurol; 1996; 69():595-8. PubMed ID: 8615185 [No Abstract] [Full Text] [Related]